Strategic alliance rather than M&A remains the preferred form of strategic interaction in the lab industry. M&A The preference of diagnostic companies to work with rather than digest each … [Read more...]
Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month
Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month
It's been a relatively quiet month on the diagnostic front in terms of both deal volume and impact. Here's a rundown of the deals that did come down. M&A CRO acquisitions were the M&A … [Read more...]
The Dx Pipeline: A Roundup of the Month’s Key New Product Launches
Abusy month in product launches included a new CE-marked IVD version of Invivoscribe Technologies' LeukoStrat CDx FLT3 Mutation Assay, which the company describes as the first companion diagnostic for … [Read more...]
FDA Watch: Two More Zika Tests Get Emergency Use Authorization
Zika made the FDA headlines this month, with two more tests receiving emergency use authorization: Thermo Fisher Scientific's TaqPath Zika Virus Kit for the qualitative detection of Zika virus RNA … [Read more...]
FDA Watch: Another First as Agency Approves NGS Oncology Companion Dx for Multiple Therapies
The FDA made a stir in May by approving a cancer drug (Keytruda (pembrolizumab) PD-1/PD-L1 inhibitor from Merck) administered on the basis of a tumor's genomic features rather than its location in the … [Read more...]
Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month
After a relatively slow March and April, business has picked up noticeably in May, June and July with deal volume increasing across all transaction model sectors. Here are the highlights from the past … [Read more...]
The Dx Pipeline: A Roundup of the Month’s Key New Product Launches
Thermo Fisher, HTG Molecular Diagnostics and Roche were among the large lab companies with product launches over the past 4 weeks. Here's a rundown of other key new products that came out. NEWLY … [Read more...]
FDA Watch: User Fees Dodge a Bullet, a Cancer Drug Approval Breaks New Ground and the Supreme Court Serves Up a Biosims Blockbuster
The FDA budget pot continues to boil. In March, the Trump administration proposed a controversial provision to double the medical user fees that diagnostics, medical device and pharma companies pay to … [Read more...]
Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month
Deal volume in May and June was noticeably higher, especially in terms of M&A activity. There was more global activity over the current than at any other point in 2017, particularly in Asia. Here … [Read more...]
FDA Speeding Approval Process, Continued User Fees Needed
The U.S. Food and Drug Administration (FDA) has been chronically plagued with understaffing, an ever expanding workload and criticism over how long the agency takes to issue approvals. And the new … [Read more...]